Thank you for your interest in the PROOF clinical research trial.

If you or someone you love has been diagnosed with cholangiocarcinoma, you may be interested in finding out more about the PROOF Trial. The PROOF Trial is evaluating an investigational drug—infigratinib—for patients who have advanced/metastatic or inoperable cholangiocarcinoma. Infigratinib is being tested as a once-daily oral alternative to chemotherapy.

Participants may be eligible if they:

  • Are at least 18 years of age
  • Have confirmed advanced/metastatic or inoperable cholangiocarcinoma

Investigational Drug:

Infigratinib—oral, once daily

Comparator:

Intravenous gemcitabine with cisplatin

Take the next step forward

Contact us today to learn more about the PROOF Trial.

mail icon

PROOFTrialInfo@QEDTx.com